2.04 -13.23% 2.15 2.27 -4.99% Finance costs (32.49) (34.40) -5.55% (62.48) (66.64) -6.24% Share of profit of investment in associate 0.61 0.81 -23.85% 1.50 1.47 1.63% Tax expense (75.16) (64.61) 16.34
and Drug Administration (CFDA), which took around 2 months, that we have got CFDA in early 2018. Sales by product category Consolidated financial statements For the three months period ended March 31
warning on issues. BP saw such an earthquake in its share price after the Gulf oil spill disaster prompted engaged investors to use their voting rights to call for the removal of the chair of the board’s
responsibilities, from BGP Spectrum, currently available and to be available in the future, as of the date of entire business transfer, including 8,100,000 ordinary shares at the par value of Baht 10 per share in
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
% % Selling Expenses to Sales 15.7% 14.3% 15.3% 13.8% Administrative Expenses 151 122 +24% 277 260 +7% % Administrative Expenses to Sales 11.4% 8.9% 10.3% 9.0% Finance Costs 15 5 +190% 27 11 +153% Share of